ANAVEX2-73 Study in Pediatric Patients With Rett Syndrome

Learn more about:
Related Clinical Trial
The Role of Dietary Calcium for the Treatment of Osteopenia in Girls With Rett Syndrome Measuring Impact of Computer Gaming on Arm Use in Rett Syndrome An Open-Label Study of Trofinetide for the Treatment of Girls Two to Five Years of Age Who Have Rett Syndrome Development of the ORCA Communication Measure for Rett Syndrome The Rett Syndrome Global Registry Open-Label Extension Study of Trofinetide for Rett Syndrome ASSESSING EMERALD AND MC10 BIOSTAMP nPOINT BIOSENSORS FOR RETT SYNDROME Predictors of Caregiver Adaptation to Pervasive Developmental Disorders A Study of the Effectiveness and Safety of Risperidone Versus Placebo in the Treatment of Children With Autistic Disorder and Other Pervasive Developmental Disorders (PDD) New Genes Involved in Molecular Etiology of Rett Syndrome Through DNA Microarray Comparative Genomic Hybridization An Open-label Extension Study of Cannabidiol Oral Solution (GWP42003-P, CBD-OS) in Patients With Rett Syndrome ANAVEX2-73 Study in Pediatric Patients With Rett Syndrome ANAVEX2-73 Study in Patients With Rett Syndrome Study of Cardiac and Paroxysmal Abnormalities in Rett Syndrome Nutritional Aspects of Rett Syndrome Sleep Abnormalities in Rare Genetic Disorders: AS, RTT, and PW Study of the Pathogenesis of Rett Syndrome Advanced Grandparental Age as a Risk Factor for Autism A Safety Study of NNZ-2566 in Pediatric Rett Syndrome Treatment of Mitochondrial Dysfunction in Rett Syndrome With Triheptanoin Biobanking of Rett Syndrome and Related Disorders Telehealth Support to Increase Physical Activity in Rett Syndrome Open-Label Extension Study of Trofinetide for the Treatment of Girls and Women With Rett Syndrome An Open Label, Exploratory Study to Investigate the Treatment Effect of Glatiramer Acetate on Girls Woth Rett Syndrome Natural History of Rett Syndrome & Related Disorders Independent Studies of Dextromethorphan and of Donepezil Hydrochloride for Rett Syndrome Study of ANAVEX2-73 in Patients With Rett Syndrome Trial of Dextromethorphan in Rett Syndrome Pharmacological Treatment of Rett Syndrome With Statins An Exploratory Trial of Ketamine for the Treatment of Rett Syndrome Analysis of the Glutathione Cycle in Children With Rett Syndrome Efficacy and Safety of Cannabidiol Oral Solution (GWP42003-P, CBD-OS) in Patients With Rett Syndrome ‘Uptime’ Participation Intervention in Girls and Women With Rett Syndrome Functional Abilities in Rett Syndrome Treatment of Rett Syndrome With rhIGF-1 (Mecasermin [rDNA]Injection) Placebo Controlled Trial of Dextromethorphan in Rett Syndrome Effects of Creatine Supplementation in Rett Syndrome Metabolic Evaluation of Nutrition in Rett Syndrome Treatment of Rett Syndrome With Recombinant Human IGF-1 A Study to Evaluate Ketamine for the Treatment of Rett Syndrome Evaluation of the Efficacy, Safety, and Tolerability of Sarizotan in Rett Syndrome With Respiratory Symptoms A Safety Study of NNZ-2566 in Patients With Rett Syndrome Genetic and Physical Characteristics of Rett Syndrome Study of Trofinetide for the Treatment of Girls and Women With Rett Syndrome (LAVENDER™) The Role of Family Functioning in Adaptation to Being a Caregiver of an Individual With Rett Syndrome A Pilot Study of an Antioxidant Cocktail vs. Placebo in the Treatment of Children and Adolescents With Rett Syndrome The Findings of MR Imaging in Rett Syndrome Phase 2 Study of EPI-743 for Treatment of Rett Syndrome Open Label Trial of Triheptanoin (UX007) in Treatment of Rett Syndrome. Pharmacological Treatment of Rett Syndrome With Glatiramer Acetate (Copaxone) Study to Assess Safety and Efficacy of Fingolimod in Children With Rett Syndrome Pilot Study of the Effects of the Desipramine on the Neurovegetative Parameters of the Child With Rett Syndrome Patients With RETT Syndrome Creatine Metabolism in Rett Syndrome

Brief Title

ANAVEX2-73 Study in Pediatric Patients With Rett Syndrome

Official Title

ANAVEX2-73-RS-003 is a Phase 2/3, Double-blind, Randomized, Placebo-controlled Safety and Efficacy Study in Pediatric Patients With RTT

Brief Summary

      ANAVEX2-73-RS-003 is a Phase 2/3, double-blind, randomized, placebo-controlled dose
      escalation safety, tolerability and efficacy study in patients 5-17 years of age with RTT
      using endpoints including multiple clinical and exploratory molecular and biochemical
      measures.
    

Detailed Description

      This Phase 2/3 efficacy study is designed as a double-blind, randomized, placebo-controlled
      study.

      This is a 12-week placebo-controlled study of ANAVEX2-73 oral solution for the treatment of
      patients with RTT 5-17 years of age. A voluntary option will be offered for all patients who
      meet the exposure criteria for ANAVEX2-73 to continue a 48-week open label extension.
    

Study Phase

Phase 2/Phase 3

Study Type

Interventional


Primary Outcome

RSBQ

Secondary Outcome

 Anxiety, Depression, and Mood Scale (ADAMS)

Condition

Rett Syndrome

Intervention

ANAVEX2-73 oral liquid

Study Arms / Comparison Groups

 ANAVEX2-73 Active
Description:  ANAVEX2-73 liquid oral solution

Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information


Recruitment Status

Drug

Estimated Enrollment

84

Start Date

July 1, 2020

Completion Date

December 1, 2022

Primary Completion Date

November 1, 2022

Eligibility Criteria

        Inclusion Criteria:

          -  Aged ≥ 5 years to 17 (inclusive).

          -  Diagnosis of classic RTT, according to 2010 criteria, and a MECP2 mutation.

          -  Post-regression stage, defined as ≥ 6 months since last loss of spoken language or
             motor (fine or gross) skills.

          -  Clinical Global Impression - Severity (CGI-S) score of 4 or greater at Screening.

          -  Current pharmacological treatment regimen, including supplements, has been stable for
             at least 4 weeks.

          -  If on AEDs, 1-4 AEDs allowed. Treatment must be stable (drug, dose, interval of
             administration) for 30 days prior to enrollment.

          -  If the subject is already receiving stable non-pharmacologic educational, behavioral,
             and/or dietary interventions, participation in these programs must have been
             continuous during the 90 days prior to the screening visit and subjects or their
             parent/caregiver/LAR will not electively initiate new or modify ongoing interventions
             for the duration of the study.

          -  The subject's caregiver/LAR is English-speaking and has sufficient language skills to
             complete the caregiver assessments and has the ability to keep accurate seizure
             diaries.

          -  If participant is a woman of childbearing potential (WOCBP#), a negative urine or
             serum pregnancy test is required to confirm she is not pregnant.

          -  Prior to the conduct of study-specific procedures, the subject's parent/caregiver/LAR
             must provide written informed consent. If applicable, the research team must attempt
             to obtain consent from both parents.

        Exclusion Criteria:

          -  Patients who have a progressive medical or neurological condition that in the opinion
             of the Investigator would interfere with the conduct of the study.

          -  Current clinically significant systemic illness that is likely to result in
             deterioration of the patient's condition or affect the patient's safety during the
             study.

          -  History or clinically evident neurologic (e.g., head trauma with loss of
             consciousness) or psychiatric condition that the Investigator deems may interfere with
             interpretability of data.

          -  Indication of liver disease, defined by serum levels of ALT (SGPT), AST (SGOT), or
             alkaline phosphatase above 3x upper limit of normal (ULN) as determined during
             screening.

          -  Treatment with immunosuppressive medications (e.g., systemic corticosteroids) within
             the last 90 days (topical and nasal corticosteroids and inhaled corticosteroids for
             asthma are permitted) or chemotherapeutic agents for malignancy within the last 3
             years.

          -  Other clinically significant abnormality on physical, neurological, laboratory, or
             electrocardiogram (ECG) examination (e.g., long QT) that could compromise the study or
             be detrimental to the participant.

          -  Any known hypersensitivity to any of the excipients contained in the study drug or
             placebo formulation.

          -  Other co-morbid or chronic illness beyond that known to be associated with RTT.

          -  Subjects who plan to initiate or change pharmacologic or nonpharmacologic intervention
             during the course of the study.

          -  Subjects taking another investigational drug currently or within the last 30 days.

          -  Any other criteria (such as a clinically significant screening blood test result),
             which in the opinion of the Investigator could interfere with the study conduct or
             outcome.

          -  Treatment with strong inhibitors or inducers of CYP3A4 or CYP2C19 is not stable (drug,
             dose) for 30 days prior to screening. Although these medications are not excluded,
             caution is advised when enrolling participants on potent CYP3A4 or CYP2C19 inducers or
             inhibitors (see respective section).

          -  Patients with hepatic and renal impairment.
      

Gender

Female

Ages

5 Years - 17 Years

Accepts Healthy Volunteers

No

Contacts

, +1(844)-689-3939, [email protected]

Location Countries

Australia

Location Countries

Australia

Administrative Informations


NCT ID

NCT04304482

Organization ID

ANAVEX2-73-RS-003


Responsible Party

Sponsor

Study Sponsor

Anavex Life Sciences Corp.

Collaborators

 Anavex Australia Pty Ltd.

Study Sponsor

, , 


Verification Date

May 2022